BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25703419)

  • 61. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST-Segment-Elevation Myocardial Infarctions.
    Schmucker J; Fach A; Mata Marin LA; Retzlaff T; Osteresch R; Kollhorst B; Hambrecht R; Pohlabeln H; Wienbergen H
    J Am Heart Assoc; 2019 Sep; 8(18):e012530. PubMed ID: 31538856
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and Safety of Prasugrel Compared With Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Wang A; Lella LK; Brener SJ
    Am J Ther; 2016; 23(6):e1637-e1643. PubMed ID: 24942006
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization.
    Savonitto S; Ferri LA; Piatti L; Grosseto D; Piovaccari G; Morici N; Bossi I; Sganzerla P; Tortorella G; Cacucci M; Ferrario M; Murena E; Sibilio G; Tondi S; Toso A; Bongioanni S; Ravera A; Corrada E; Mariani M; Di Ascenzo L; Petronio AS; Cavallini C; Vitrella G; Rogacka R; Antonicelli R; Cesana BM; De Luca L; Ottani F; De Luca G; Piscione F; Moffa N; De Servi S;
    Circulation; 2018 Jun; 137(23):2435-2445. PubMed ID: 29459361
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study.
    Jacobsen MR; Jabbari R; Engstrøm T; Grove EL; Glinge C; Pedersen F; Holmvang L; Køber L; Torp-Pedersen C; Maeng M; Veien K; Freeman P; Charlot MG; Kelbæk H; Sørensen R
    Eur Heart J Cardiovasc Pharmacother; 2023 Nov; 9(7):617-626. PubMed ID: 37403404
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.
    Motovska Z; Hlinomaz O; Kala P; Hromadka M; Knot J; Varvarovsky I; Dusek J; Jarkovsky J; Miklik R; Rokyta R; Tousek F; Kramarikova P; Svoboda M; Majtan B; Simek S; Branny M; Mrozek J; Cervinka P; Ostransky J; Widimsky P;
    J Am Coll Cardiol; 2018 Jan; 71(4):371-381. PubMed ID: 29154813
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.
    Faggioni M; Baber U; Chandrasekhar J; Sartori S; Claessen BE; Rao SV; Vogel B; Effron MB; Poddar K; Farhan S; Kini A; Weintraub W; Toma C; Sorrentino S; Weiss S; Snyder C; Muhlestein JB; Kapadia S; Keller S; Strauss C; Aquino M; Baker B; Defranco A; Pocock S; Henry T; Mehran R
    Int J Cardiol; 2019 Jan; 275():31-35. PubMed ID: 30391067
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immediate response to prasugrel loading in patients with ST-elevation myocardial infarction: Predictors and outcome.
    Koifman E; Beigel R; Herscovici R; Fefer P; Rozenberg N; Sabbag A; Biton Y; Segev A; Shechter M; Asher E; Matetzky S
    Thromb Res; 2016 Aug; 144():176-81. PubMed ID: 27386796
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel.
    Widimsky P; Motovska Z; Bolognese L; Dudek D; Hamm C; Tanguay JF; Ten Berg J; Brown E; LeNarz L; Miller DL; Montalescot G;
    Heart; 2015 Aug; 101(15):1219-24. PubMed ID: 26060122
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
    Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 73. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects.
    De Filippo O; D'Ascenzo F; Raposeiras-Roubin S; Abu-Assi E; Peyracchia M; Bocchino PP; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Templin C; Wilton SB; Omedè P; Velicki L; Xanthopoulou I; Correia L; Cerrato E; Rognoni A; Fabrizio U; Nuñez-Gil I; Iannaccone M; Montabone A; Taha S; Fujii T; Durante A; Song X; Gili S; Magnani G; Varbella F; Kawaji T; Blanco PF; Garay A; Quadri G; Alexopoulos D; Caneiro Queija B; Huczek Z; Cobas Paz R; González Juanatey JR; Cespón Fernández M; Nie SP; Muñoz Pousa I; Kawashiri MA; Gallo D; Morbiducci U; Conrotto F; Montefusco A; Dominguez-Rodriguez A; López-Cuenca A; Cequier A; Iñiguez-Romo A; Usmiani T; Rinaldi M; De Ferrari GM
    Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):31-42. PubMed ID: 31511896
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction.
    Vogel RF; Delewi R; Angiolillo DJ; Wilschut JM; Lemmert ME; Diletti R; van Vliet R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Krucoff MW; van Mieghem NM; Smits PC; Vlachojannis GJ
    JACC Cardiovasc Interv; 2021 Jun; 14(12):1323-1333. PubMed ID: 34167672
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction.
    Jacobsen MR; Engstrøm T; Torp-Pedersen C; Gislason G; Glinge C; Butt JH; Fosbøl EL; Holmvang L; Pedersen F; Køber L; Jabbari R; Sørensen R
    Int J Cardiol; 2021 Nov; 342():15-22. PubMed ID: 34311012
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The paradox of clopidogrel use in patients with acute coronary syndromes and diabetes: insight from the Diabetes and Acute Coronary Syndrome Registry.
    Ferlini M; Musumeci G; Grieco N; Rossini R; De Servi S; Mafrici A; Sponzilli C; Demarchi A; Assanelli EM; Camisasca P; Chizzola G; Corrada E; Farina A; Pedrinazzi C; Lettieri C; Oltrona Visconti L
    Coron Artery Dis; 2018 Jun; 29(4):309-315. PubMed ID: 29309286
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
    Aradi D; Gross L; Trenk D; Geisler T; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Ruzsa Z; Ungi I; Rizas KD; May AE; Mügge A; Zeiher AM; Holdt L; Huber K; Neumann FJ; Koltowski L; Huczek Z; Hadamitzky M; Massberg S; Sibbing D
    Eur Heart J; 2019 Jun; 40(24):1942-1951. PubMed ID: 31226213
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rationale, Design, and Baseline Characteristics of the Prospective Japan Acute Myocardial Infarction Registry (JAMIR).
    Honda S; Nishihira K; Kojima S; Takegami M; Asaumi Y; Suzuki M; Kosuge M; Takahashi J; Sakata Y; Takayama M; Sumiyoshi T; Ogawa H; Kimura K; Yasuda S;
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):97-103. PubMed ID: 30470946
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention.
    Koyabu Y; Abe S; Sakuma M; Kanaya T; Obi S; Yoneda S; Toyoda S; Nakajima T; Inoue T
    Intern Med; 2019 Aug; 58(16):2315-2322. PubMed ID: 31118376
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses].
    Abaci A
    Turk Kardiyol Dern Ars; 2015 Oct; 43 Suppl 2():1-6. PubMed ID: 27326444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.